Published in Proc Natl Acad Sci U S A on February 26, 2002
Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol Mol Biol Rev (2004) 2.60
In vivo, noninvasive, label-free detection and eradication of circulating metastatic melanoma cells using two-color photoacoustic flow cytometry with a diode laser. Cancer Res (2009) 2.48
Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res (2009) 1.44
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature. J Biol Chem (2007) 1.41
Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A (2003) 1.38
Anthrax lethal factor-cleavage products of MAPK (mitogen-activated protein kinase) kinases exhibit reduced binding to their cognate MAPKs. Biochem J (2004) 1.33
Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response. PLoS Pathog (2005) 1.28
Anthrax lethal factor represses glucocorticoid and progesterone receptor activity. Proc Natl Acad Sci U S A (2003) 1.16
Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. Proc Natl Acad Sci U S A (2010) 1.11
Targeting the anthrax receptors, TEM-8 and CMG-2, for anti-angiogenic therapy. Front Biosci (Landmark Ed) (2011) 1.10
Targeting HER2-positive cancer cells with receptor-redirected anthrax protective antigen. Mol Oncol (2012) 1.07
Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem (2008) 1.04
Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene (2009) 1.02
Toxin-based therapeutic approaches. Toxins (Basel) (2010) 1.00
Targeting the RAS pathway in melanoma. Trends Mol Med (2011) 0.98
Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity. Curr Immunol Rev (2006) 0.96
Photoacoustic Imaging for Cancer Detection and Staging. Curr Mol Imaging (2013) 0.91
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Mol Cancer Ther (2008) 0.91
Oncogenic B-Raf signaling in melanoma cells controls a network of microRNAs with combinatorial functions. Oncogene (2012) 0.91
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther (2010) 0.89
Broad expression analysis of human ANTXR1/TEM8 transcripts reveals differential expression and novel splizce variants. PLoS One (2012) 0.89
Cationic polyamines inhibit anthrax lethal factor protease. BMC Pharmacol (2006) 0.88
Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz) (2007) 0.85
MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells. PLoS One (2011) 0.84
Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin. Toxins (Basel) (2010) 0.84
Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin. PLoS One (2009) 0.84
Molecular determinants for a cardiovascular collapse in anthrax. Front Biosci (Elite Ed) (2014) 0.83
Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity. Transl Oncol (2013) 0.81
An anthrax lethal factor mutant that is defective at causing pyroptosis retains proapoptotic activity. FEBS J (2009) 0.81
Raf-1 activation prevents caspase 9 processing downstream of apoptosome formation. J Signal Transduct (2010) 0.79
Conditioned Media from Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells Inhibits Melanogenesis by Promoting Proteasomal Degradation of MITF. PLoS One (2015) 0.78
Pseudomonas aeruginosa exotoxin A reduces chemoresistance of oral squamous carcinoma cell via inhibition of heat shock proteins 70 (HSP70). Yonsei Med J (2010) 0.78
Channel-forming bacterial toxins in biosensing and macromolecule delivery. Toxins (Basel) (2014) 0.77
Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF). Transl Oncol (2015) 0.77
Induction of Apoptosis by PQ1, a Gap Junction Enhancer that Upregulates Connexin 43 and Activates the MAPK Signaling Pathway in Mammary Carcinoma Cells. Int J Mol Sci (2016) 0.76
Identification of a substrate-selective exosite within the metalloproteinase anthrax lethal factor. J Biol Chem (2016) 0.75
Engineered single nucleotide polymorphisms in the mosquito MEK docking site alter Plasmodium berghei development in Anopheles gambiae. Parasit Vectors (2014) 0.75
Heterogeneous Family of Cyclomodulins: Smart Weapons That Allow Bacteria to Hijack the Eukaryotic Cell Cycle and Promote Infections. Front Cell Infect Microbiol (2017) 0.75
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol (1992) 34.17
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 13.93
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (1998) 10.53
A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A (1995) 10.25
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (1991) 9.39
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 7.97
Signal transduction through MAP kinase cascades. Adv Cancer Res (1998) 5.65
Cancer statistics, 1997. CA Cancer J Clin (1997) 5.22
Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem Biophys Res Commun (1998) 4.44
Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci (1990) 4.30
Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem J (2000) 3.83
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene (1999) 3.32
Hyperexpression of mitogen-activated protein kinase in human breast cancer. J Clin Invest (1997) 3.26
Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett (1999) 3.00
Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res (1992) 2.62
New insights into the control of MAP kinase pathways. Exp Cell Res (1999) 2.39
The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J Natl Cancer Inst (1999) 1.61
The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol (1999) 1.54
Inhibition of the mitogen-activated protein kinase pathway triggers B16 melanoma cell differentiation. J Biol Chem (1998) 1.40
Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A (2001) 1.28
In situ visualization of intratumor growth factor signaling: immunohistochemical localization of activated ERK/MAP kinase in glial neoplasms. Am J Pathol (1998) 1.21
Anthrax toxins. Cell Mol Life Sci (1999) 1.20
U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways. Cancer Res (2000) 1.09
Analysis of signaling protein kinases in human colon or colorectal carcinomas. Dig Dis Sci (1998) 1.04
Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 14.30
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res (2009) 3.11
c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res (2007) 2.83
Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J Biol Chem (2003) 2.32
C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer (2005) 2.25
Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations. Proc Natl Acad Sci U S A (2007) 2.15
HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem (2003) 2.08
Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A (2003) 1.90
Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc Natl Acad Sci U S A (2006) 1.85
Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the initiation of DNA synthesis and the specificity of RNase H cleavage in vivo. Proc Natl Acad Sci U S A (2002) 1.85
High expression of the Met receptor in prostate cancer metastasis to bone. Urology (2002) 1.83
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo. Cancer Res (2008) 1.76
HGF/SF-Met signaling in tumor progression. Cell Res (2005) 1.61
The decline in U.S. cancer mortality in people born since 1925. Cancer Res (2009) 1.61
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res (2005) 1.55
Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene (2002) 1.47
Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proc Natl Acad Sci U S A (2009) 1.42
Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A (2005) 1.40
Overexpression of sprouty 2 inhibits HGF/SF-mediated cell growth, invasion, migration, and cytokinesis. Oncogene (2004) 1.37
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. Microb Pathog (2007) 1.36
Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. Cancer Res (2002) 1.32
Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease. Proc Natl Acad Sci U S A (2009) 1.28
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res (2010) 1.28
Mig-6, signal transduction, stress response and cancer. Cell Cycle (2007) 1.28
Mutation of amino acids in the connection domain of human immunodeficiency virus type 1 reverse transcriptase that contact the template-primer affects RNase H activity. J Virol (2003) 1.28
BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther (2005) 1.27
Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alpha. J Biol Chem (2002) 1.26
Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene (2005) 1.25
Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A (2011) 1.20
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. Proc Natl Acad Sci U S A (2005) 1.16
RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival. Cancer Res (2004) 1.15
Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis. Virology (2004) 1.13
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clin Cancer Res (2006) 1.08
Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene (2005) 1.06
MET: a critical player in tumorigenesis and therapeutic target. Cold Spring Harb Perspect Biol (2013) 1.06
Effects of mutations in the G tract of the human immunodeficiency virus type 1 polypurine tract on virus replication and RNase H cleavage. J Virol (2004) 1.06
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin. PLoS Pathog (2007) 1.05
MEK genomics in development and disease. Brief Funct Genomics (2012) 1.04
A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J Transl Med (2008) 1.03
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Mol Cancer Ther (2008) 1.00
Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes Cancer (2013) 0.98
Pathophysiology of anthrax. Front Biosci (Landmark Ed) (2009) 0.96
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy. Cell Cycle (2008) 0.96
Mutations in the U5 region adjacent to the primer binding site affect tRNA cleavage by human immunodeficiency virus type 1 reverse transcriptase in vivo. J Virol (2007) 0.94
Involvement of domain II in toxicity of anthrax lethal factor. J Biol Chem (2004) 0.94
Mutations in the thumb allow human immunodeficiency virus type 1 reverse transcriptase to be cleaved by protease in virions. J Virol (2009) 0.94
Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreous. Invest Ophthalmol Vis Sci (2013) 0.94
Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol Cancer Ther (2009) 0.91
A mouse model of activating Met mutations. Cell Cycle (2005) 0.91
Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation. Proc Natl Acad Sci U S A (2014) 0.91
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells. Mol Cancer Ther (2008) 0.91
In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia (2006) 0.90
MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance. Mol Cancer Res (2013) 0.90
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution. Int J Oncol (2008) 0.90
Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res (2005) 0.89
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther (2010) 0.89
Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. Clin Cancer Res (2007) 0.88
Xp38gamma/SAPK3 promotes meiotic G(2)/M transition in Xenopus oocytes and activates Cdc25C. EMBO J (2003) 0.87
An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med (2006) 0.86
Met decoys: will cancer take the bait? Cancer Cell (2004) 0.86
Developmental biology: an arresting activity. Nature (2002) 0.84
Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis. Mol Cancer Res (2009) 0.84
Met amplification and tumor progression in Cdkn2a-deficient melanocytes. Pigment Cell Melanoma Res (2009) 0.84
Perturbation of mouse retinal vascular morphogenesis by anthrax lethal toxin. PLoS One (2009) 0.84
MEK2 is sufficient but not necessary for proliferation and anchorage-independent growth of SK-MEL-28 melanoma cells. PLoS One (2011) 0.84
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxin. Invest Ophthalmol Vis Sci (2011) 0.83
Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. Proc Natl Acad Sci U S A (2011) 0.83
Anthrax fusion protein therapy of cancer. Curr Protein Pept Sci (2002) 0.83
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma. Mol Cancer Ther (2013) 0.83
Novel protein targeted therapy of metastatic melanoma. Curr Pharm Des (2003) 0.83
Treatment with suboptimal doses of raltegravir leads to aberrant HIV-1 integrations. Proc Natl Acad Sci U S A (2013) 0.82
A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro. Clin Dev Immunol (2013) 0.82
HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met. Neoplasia (2006) 0.82
Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/scatter factor. Mol Imaging (2003) 0.82
Identification of a met-binding peptide from a phage display library. Clin Cancer Res (2007) 0.82
Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways. Methods Enzymol (2008) 0.82
Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stromal cells. Exp Cell Res (2003) 0.81
Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody. Clin Cancer Res (2003) 0.81
Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther (2013) 0.80
RTK inhibition: looking for the right pathways toward a miracle. Future Oncol (2012) 0.79
Cancer-type regulation of MIG-6 expression by inhibitors of methylation and histone deacetylation. PLoS One (2012) 0.79
Recombinant viral-like particles of parvovirus B19 as antigen carriers of anthrax protective antigen. In Vivo (2006) 0.79
Characterization of MPF and MAPK activities during meiotic maturation of Xenopus tropicalis oocytes. Dev Biol (2002) 0.78
Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer. Mol Cancer Ther (2010) 0.78
Xenopus tropicalis oocytes: more than just a beautiful genome. Methods Mol Biol (2006) 0.76
Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles. PLoS One (2010) 0.76
A tribute to George F. Vande Woude, a man of character: 2006 Scientific Symposium Winning the War against Cancer: from Genomics to Bedside and Back. Cancer Res (2007) 0.75
The distinct stage-specific effects of 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid on the activation of MAP kinase and Cdc2 kinase in Xenopus oocyte maturation. Cell Signal (2005) 0.75
Advances in Cancer Research: Centennial Volume. Introduction. Adv Cancer Res (2008) 0.75